

1 **Diversity and selection analyses identify transmission-blocking**
2 **antigens as the optimal vaccine candidates in *Plasmodium falciparum***

3
4 Ilinca I. Ciubotariu¹, Bradley K. Broyles¹, Shaojun Xie², Jyothi Thimmapuram², Mulenga C. Mwenda³,
5 Brenda Mambwe³, Conceptor Mulube³, Japhet Matoba⁴, Jessica L. Schue⁵, William J. Moss^{6,7}, Daniel J.
6 Bridges⁸, Qixin He^{1*}, and Giovanna Carpi^{1,9*}

7
8 ¹ Department of Biological Sciences, Purdue University, West Lafayette, Indiana, USA

9 ² Bioinformatics Core, Purdue University, West Lafayette, Indiana, USA

10 ³ PATH-Malaria Control and Elimination Partnership in Africa (MACEPA), National Malaria Elimination
11 Centre, Lusaka, Zambia

12 ⁴ Macha Research Trust, Choma, Zambia

13 ⁵ Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore,
14 Maryland, USA

15 ⁶ The W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Malaria
16 Research Institute, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA

17 ⁷ Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland,
18 USA

19 ⁸ PATH, Lusaka, Zambia

20 ⁹ Purdue Institute of Inflammation, Immunology and Infectious Disease, West Lafayette, Indiana, USA

21 * Joint senior authors

22

23 **Corresponding authors:**

24 Correspondence to Giovanna Carpi (gcarpi@purdue.edu) and Qixin He (heqixin@purdue.edu).

25

26

27 **Summary**

28 **Background**

29 A highly effective vaccine for malaria remains an elusive target, at least in part due to the under-
30 appreciated natural parasite variation. This study aimed to investigate genetic and structural variation,
31 and immune selection of leading malaria vaccine candidates across the *Plasmodium falciparum*'s life
32 cycle.

33 **Methods**

34 We analyzed 325 *P. falciparum* whole genome sequences from Zambia, in addition to 791 genomes from
35 five other African countries available in the MalariaGEN Pf3k Rdatabase. Ten vaccine antigens spanning
36 three life-history stages were examined for genetic and structural variations, using population genetics
37 measures, haplotype network analysis, and 3D structure selection analysis.

38 **Findings**

39 Among the ten antigens analyzed, only three in the transmission-blocking vaccine category display *P.*
40 *falciparum* 3D7 as the dominant haplotype. The antigens *AMA1*, *CSP*, *MSP1₁₉* and *CeITOS*, are much
41 more diverse than the other antigens, and their epitope regions are under moderate to strong balancing
42 selection. In contrast, *Rh5*, a blood stage antigen, displays low diversity yet slightly stronger immune
43 selection in the merozoite-blocking epitope region. Except for *CeITOS*, the transmission-blocking antigens
44 *Pfs25*, *Pfs48/45*, *Pfs230*, *Pfs47*, and *Pfs28* exhibit minimal diversity and no immune selection in epitopes
45 that induce strain-transcending antibodies, suggesting potential effectiveness of 3D7-based vaccines in
46 blocking transmission.

47 **Interpretations**

48 These findings offer valuable insights into the selection of optimal vaccine candidates against *P.*
49 *falciparum*. Based on our results, we recommend prioritizing conserved merozoite antigens and
50 transmission-blocking antigens. Combining these antigens in multi-stage approaches may be particularly
51 promising for malaria vaccine development initiatives.

52 **Funding**

53 Purdue Department of Biological Sciences; Puskas Memorial Fellowship; National Institute of Allergy and
54 Infectious Diseases (U19AI089680).

55 **Research in context**

56 **Evidence before this study**

57 Decades of research on the most virulent malaria parasite, *Plasmodium falciparum*, have yielded multiple
58 antigen candidates of pre-erythrocytic, blood-stage, and transmission-blocking vaccines in varying stages
59 of development from preclinical development to more advanced clinical trials. The malaria vaccine,
60 RTS,S/AS01, which was constructed using the C-terminal and NANP repeat region of the
61 Circumsporozoite Protein (CSP) from the African reference strain 3D7, was approved and recommended
62 for use in 2021. However, the vaccine's lower efficacy is likely a result of the genetic polymorphism of the
63 target antigen shown by studies on natural variation in CSP. Similarly, another more recent pre-
64 erythrocytic vaccine, R21/Matrix-M, showed great promise in clinical trials and was recommended in late
65 2023 by the WHO for use for prevention of malaria in children, but is also multi-dose and CSP-based. To
66 maximize vaccine efficacy, it would be more strategic to first understand diversity and variation of
67 antigens across the three types of vaccine classes, targeting various stages of the *P. falciparum* life cycle.
68 Previous studies have reported analyses of vaccine candidate antigens but were mostly limited to pre-
69 erythrocytic and blood-stage antigens, with less focus on transmission-blocking antigens. These studies
70 revealed that most of the pre-erythrocytic and blood-stage antigens are of high diversity due to balancing
71 selection, posing challenges for vaccine design to encompass the antigenic variation.

72 A search conducted on PubMed on April 1, 2024, for relevant published research which used the terms
73 "malaria vaccine", "*Plasmodium falciparum*" [not "*vivax*"], "selection" and "diversity" yielded 48 studies
74 between 1996 and the present day, with only 14 published studies in the past 3 years. This emphasizes
75 the need for more studies assessing genetic diversity and selection of potential *P. falciparum* vaccine
76 candidates to aid in more effective vaccine development efforts. A similar search with the terms
77 "transmission-blocking vaccine", "malaria", "*Plasmodium falciparum*", not "*vivax*", "selection" and

78 “diversity” without any date or language restrictions revealed three relevant studies. This warrants future
79 studies to explore transmission-blocking vaccines in this context.

80 **Added value of this study**

81 By comparing the genetic and structural analyses of transmission-blocking antigens with pre-erythrocytic
82 and blood-stage antigens, we identify promising *P. falciparum* vaccine antigens characterized by their
83 conservation with low balancing selection and the presence of infection/transmission-blocking epitopes,
84 which are essential for informing the development of new malaria vaccines. This comprehensive workflow
85 can be adopted for studying the genetic and structural variation of other *P. falciparum* vaccine targets
86 before developing the next generation of malaria vaccines for effectiveness against natural parasite
87 populations.

88 **Implications of this study**

89 Our suggested strategies for designing malaria vaccines include two possible approaches. We
90 emphasize the development of a multi-stage vaccine that combines critical components such as anti-
91 merozoite (*Rh5*) and transmission-blocking antigens (*Pfs25*, *Pfs28*, *Pfs48/45*, *Pfs230*). Alternatively, we
92 suggest the creation of transmission-blocking vaccines specifically targeting *Pfs25*, *Pfs28* and *Pfs48/45*.
93 These innovative approaches show great potential in advancing the development of more potent and
94 effective malaria vaccines for the future.

95 **Introduction**

96 For preventing and controlling many infectious diseases, vaccines are vital tools that increase immunity,
97 leading to reduced disease severity, incidence, and transmission. For malaria, a vector-borne disease
98 caused by *Plasmodium* species parasites, vaccine strategies can be characterized by the three main
99 parasite life-cycle stages that they target (Fig. 1). Firstly, pre-erythrocytic vaccines target sporozoites
100 inoculated by *Anopheles* mosquitoes into the human skin before they reach the liver or infected
101 hepatocytes, with the aim of preventing initial infection^{1,2}. Some pre-erythrocytic subunit vaccine
102 candidates^{3,4} for *P. falciparum* include the first licensed malaria vaccine RTS,S/AS01⁵, low-dose

103 R21/Matrix-M vaccine (currently approved for use in some countries⁶), and the full-length *CSP*⁷. Blood-
104 stage vaccines predominantly target merozoites or infected erythrocytes to prevent replication and clinical
105 illness, and some candidates include *AMA1*, *MSP1*, and *Rh5*^{3,8}. Transmission-blocking vaccines target
106 antigens expressed in the gametes and ookinete stages in the mosquito midgut; this vaccine type induces
107 antibodies in humans that impair the parasite's development inside the mosquito and thus prevent
108 subsequent transmission. Some examples of transmission-blocking vaccine candidates are *Pfs25*,
109 *Pfs230*, and *Pfs48/45*^{3,9,10}.

110 To date, among the numerous preclinical and clinical trials of these classes of vaccines, RTS,S and R21
111 are the only two malaria vaccine licensed and recommended by the WHO. The former is approved for
112 widespread use among children in sub-Saharan Africa and other regions with moderate to high *P.*
113 *falciparum* malaria transmission^{5,11-14} and the latter by regulators in Ghana, Nigeria, and Burkina Faso^{6,15}.

114 While this is a tremendous breakthrough for the field considering the complexity of the parasite life cycle
115 and the correspondingly large number of protein-coding genes (>5,000) in the *Plasmodium* genome¹⁶,
116 there is a wealth of vaccine targets¹⁷⁻²⁰. Despite the large number, about 60% of the genes code for
117 putative proteins²¹ and have unknown function^{16,22}, which poses an enormous challenge, and many of
118 these 5300+ protein coding genes do not make attractive vaccine targets due to expression patterns,
119 localization, high genetic variability, etc., and candidates must be experimentally validated for vaccine
120 development²³. Yet, despite decades of effort, noticeably little progress past early phase clinical trials for
121 many of these other targets^{24,25}. Furthermore, the RTS,S vaccine shows only modest efficacy ranging
122 from 30% to 40% that wanes with time and requires four doses to reduce severe malaria by 30%^{12,26-28}.

123 This low efficacy has been attributed to the high genetic diversity and many polymorphic residues of the
124 target antigen, *CSP*^{12,24,29}. Notably, RTS,S was developed using a standard laboratory strain (*P.*
125 *falciparum* 3D7), which originates from Africa but is not highly representative³⁰ and has low frequency
126 within many parasite populations^{29,31-33}. This underlines the need to consider *CSP*'s functional importance
127 as well as the natural variation in the population, especially in epitope regions^{25,34}, when designing a
128 vaccine. In recent years, vaccines based on regions of conserved or semi-conserved epitopes are
129 emerging in other important yet antigenically diverse pathogens such as influenza virus and
130 meningococcus³⁵⁻³⁷.

131 With the release of thousands of publicly available *P. falciparum* whole genome sequences (WGS), it is
132 possible to study the natural genetic and functional variation of targets for malaria vaccine candidate
133 antigens, yet, to date few studies have done so^{34,38-40}. Two recent studies reported comprehensive
134 analyses of vaccine candidate antigens^{25,41}, but were focused primarily on pre-erythrocytic and blood-
135 stage antigens, with limited inclusion of transmission-blocking antigens. Here, we aimed to characterize
136 the natural genetic and structural variation of ten *P. falciparum* vaccine antigens spanning the three
137 different vaccine classes, including transmission-blocking antigens. We focused on Africa which carries
138 the heaviest burden of malaria, and augmented parasite genomic data from Zambia, where malaria
139 continues to be endemic and a major public health with over 8 million cases and 1300 deaths reported in
140 2022⁴².

141 **Methods**

142 **Ethics Statement**

143 The parents or legal guardians provided parental permission for study participants and this study was
144 conducted with the approval of the Biomedical Research Ethics Committee from the University of Zambia
145 (Ref 011-02-18) and from the Zambian National Health Research Authority.

146

147 **Sample Selection and Processing**

148 This work is a secondary analysis of a larger parent study focused on understanding malaria transmission
149 across Zambia and establishing a baseline for parasite genetic metrics for this country that are
150 informative about transmission intensity, genetic relatedness between parasites, and selection⁴³. Briefly,
151 dried blood spot (DBS) samples were collected as part of the 2018 Zambia Malaria Indicator Survey
152 (MIS), which used a nationally representative two-stage stratified clustering sampling strategy to obtain
153 samples across Zambia for the estimation of malaria prevalence⁴⁴. The 2018 MIS included DBS samples
154 from children under the age of 5 from 179 standard enumeration areas from across ten provinces, with
155 high transmission provinces oversampled⁴⁴. Due to undersampling in the low transmission provinces
156 (Central, Lusaka and Southern), we augmented the DBS samples from the Zambia 2018 MIS with DBS

157 samples from Southern Province collected in the community surveillance program from the Southern and
158 Central Africa International Centers of Excellence for Malaria Research (ICEMR)⁴⁵. These additional
159 samples temporally matched the MIS (from 2018-2019) and were collected as part of a longitudinal cohort
160 study conducted to understand sources of focal transmission from an area with an expected relatively
161 high number of incident malaria cases.

162 In total we included 459 PET-PCR positive *P. falciparum* samples from seven provinces⁴³ and additional
163 28 PCR positive *P. falciparum* samples from Southern Province for sequencing. The samples were
164 processed for genomic DNA extraction as previously described^{43,46} and then genomic library preparation,
165 parasite enrichment and sequencing were carried out.

166

167 **Whole-Genome Sequencing**

168 To selectively enrich and sequence whole *P. falciparum* genomes from DBS we used a 4-plexed hybrid
169 capture method previously described⁴³. Genomic library preparation, hybridization capture, and
170 sequencing was conducted at the Yale Center for Genomic Analysis (YCGA). Samples were sequenced
171 using 101 bp paired-end read sequencing on an Illumina NovaSeq 6000 with a target of 30 million reads
172 per sample.

173

174 **Acquisition of Additional Genomic Data**

175 To contextualize Zambian *P. falciparum* genome diversity within Africa, we included and analyzed 781
176 publicly available *P. falciparum* WGS data from 5 countries across West, Central, and East Africa
177 (Democratic Republic of the Congo, Ghana, Guinea, Malawi, and Tanzania) from the MalariaGEN Pf3k
178 project release 5.1 (<https://www.malariagen.net/data/pf3k-5>) and the MalariaGEN *P. falciparum*
179 Community Project (<http://www.malariagen.net/resource/16>). Raw Fastq files were downloaded from SRA
180 using pysradb (<https://github.com/saketkc/pysradb>)⁴⁷ and processed in the same way as the newly
181 sequenced WGS.

182

183 **Read Mapping and Variant Identification**

184 We identified *P. falciparum* genomic variation from whole genome sequence data using a bioinformatics
185 pipeline previously described⁴⁸. Briefly, the Illumina paired-end reads were trimmed for low-quality bases
186 (Phred-scaled base quality <30) and mapped to the *P. falciparum* 3D7 reference genome
187 (<ftp://ftp.sanger.ac.uk/pub/project/pathogens/gff3/2015-08/Pfalciparum.genome.fasta.gz>) using BWA-
188 MEM v0.7.17⁴⁹. Aligned reads for the 1248 samples (487 from Zambia and 781 from Pf3k) were marked
189 for duplicates and sorted using Picard Tools 2.20.8. For variant calling only samples with >50% of the
190 regions spanning the selected antigens (Table 1) with >5X read coverage were included, resulting in a
191 total of 1092 *P. falciparum* WGS samples. Variants were called using GATK v4.1.4.1 following best
192 practices (<https://software.broadinstitute.org/gatk/best-practices>)^{50,51}. We applied GATK Base Quality
193 Score Recalibration using default parameters and using variants from the *P. falciparum* crosses 1.0
194 release as a set of known sites (<ftp://www.malariagen.net/data/pf-crosses-1.0>)⁵². GATK HaplotypeCaller
195 in GVCF mode was used to call single-sample variants (*ploidy* 2 and *standard-min-confidence-threshold*
196 *for calling* = 30), followed by GenotypeGVCFs to genotype the cohort. We restricted our analyses to
197 variants from the 14 nuclear chromosomes only, excluding variants from telomeric and hypervariable
198 regions (<ftp://ngs.sanger.ac.uk/production/malaria/pf-crosses/1.0/regions-20130225.onebased.txt>). We
199 further removed variants with VQSLOD <0 and SNPs with missingness >0.2. After variant filtering, we
200 scored 426,757 genome-wide SNPs across the 1092 samples.
201 Variants were functionally annotated with SnpEff (version 4.3t) for genomic variant annotations and
202 functional effect prediction⁵³.

203

204 **Multiplicity of Infection**

205 To ensure high quality haplotype reconstruction, we first determined the multiplicity of infection (MOI) for
206 each sample using within-sample F statistic (F_{WS})⁵⁴ implemented in the R moimix package (available
207 at <https://github.com/bahlolab/moimix>). F_{WS} scores infections on a continuous scale of multiplicity, with
208 infections having an $F_{WS} > 0.95$ considered clonal (MOI=1), those with $F_{WS} < 0.95$ and > 0.8 containing
209 two strains (MOI=2), and those with $F_{WS} < 0.8$ harboring more than two strains (MOI>2). F_{WS} metric
210 derived from the 426,757 genome-wide SNPs were used to stratify samples into single infections, two
211 infections or more than two infections.

212

213 **Selection of Vaccine Candidate Antigens**

214 Antigens were selected based on their inclusion¹⁴ in either two licensed and recommended malaria
215 vaccines (e.g. *CSP*)²⁸, clinical development in Phase I (e.g. *AMA1*, *Rh5*, *MSP1*, *Pfs25*, *Pfs48/45*, and
216 *Pfs230*)³, clinical development in Phase II (e.g. *Rh5* and *Pfs230*)⁵⁵⁻⁵⁷, or their recognition as a promising
217 vaccine target (e.g. *Pfs47*, *Pfs28*, and *CeITOS*)^{58,59}. The ten selected antigens encompassed all parasite
218 life cycle stages (Table 1 and Fig. 1), and genomic information and coordinates are provided in Table S1.

219

220 **Haplotype Reconstruction**

221 Vaccine target regions (Table S1) were extracted from the filtered VCF file (VQSLOD <0) in BED format
222 using vcftools (version 0.1.16). Haplotypes were reconstructed using a custom code available at
223 https://github.com/giocarpi/Pf_capture_div_code, which converted the VCF file to FASTA format,
224 incorporating all variants (SNPs and INDELS) within coding sequences (CDS) relative to the *P. falciparum*
225 3D7 reference gene sequences. For a given variant position in a sample, a minimum read depth was
226 required to be 5 for samples of MOI=1 and a minimum read depth of 10 for samples of MOI=2. A
227 minimum minor allele proportion for a heterozygous call to be made was set to 0.2. If the mean frequency
228 of minor alleles was below 0.4, these minor alleles constituted a minor haplotype, which would be
229 included in the following analyses; otherwise, the minor haplotype was not retained (according to paper²⁵
230 and code). Samples failing read depth criteria were excluded from downstream analysis, as were
231 samples containing one or more 'N' nucleotides.

232

233 **Genetic Diversity Analysis**

234 The software DNA Sequence Polymorphism (DnaSP) version 6.12.03 was used to calculate the number
235 of unique haplotypes (h) of each respective vaccine candidate antigen in each country, the number of
236 polymorphic sites (S), and the average number of pairwise nucleotide differences (k) between samples
237 from within and between countries⁶⁰. Furthermore, we calculated the haplotype diversity (Hd) for each
238 antigen, with 1 representing a population in which every haplotype is unique and 0 equating a population
239 where each haplotype is identical. Nei's nucleotide diversity statistic⁶¹ (π) within each country and among

240 all samples was also calculated, which represents the average number of nucleotide differences between
241 haplotypes drawn from the same population. *Tajima's D* statistic values⁶¹⁻⁶³ were calculated using
242 Molecular Evolutionary Genetics Analysis (MEGA X) version 10.1.7 to measure selection (*Tajima's D*
243 values that are approximately zero occur in neutral conditions, >1 indicates balancing selection, and <1
244 represents purifying selection). Gaps in the multiple sequence alignments were treated as complete
245 deletion. To assess the genealogical relationships between the haplotypes found in Pf3k from African
246 countries and those from Zambia for each vaccine candidate antigen of interest, we constructed
247 haplotype networks based on the method by Templeton, Crandall, and Sing (TCS) using PopArt version
248 1.7^{64,65}.

249

250 **Structural Analyses**

251 Protein structures used for the downstream analyses were either selected from existing solved ones or
252 generated from AlphaFold2⁶⁶. PDB structures were retrieved from the Research Collaboratory for
253 Structural Bioinformatics (RCSB) database on 5/23/2023. The final solved structures to be used for each
254 protein were selected based on three criteria: 1) the structure was based on *P. falciparum* 3D7 reference
255 gene sequences; 2) most complete in terms of gene coverage; 3) resolved as many residues with
256 polymorphisms as possible. Often, the SNP-containing residues occurred in solvent-exposed loop regions
257 that were not resolved in published Protein Data Bank (PDB) structures. In these cases (i.e., *AMA1*, *Rh5*,
258 *Pfs230* (D1, D2), *Pfs25*, *MSP1₁₉*) and the case of no solved structures for *P. falciparum* (i.e., *Pfs47*,
259 *CeITOS*), we assessed the qualities of AlphaFold2's predictions of these structures, that is whether the
260 RMSD is small or < 3 Å^{67,68} (Fig. S3). *Pfs230* (D1, D2), *Pfs25*, *Pfs4845*, and *MSP1₁₉* were successfully
261 folded by AlphaFold2, agreeing with the native fold at or below 2 Å Root Mean Square Deviation (RMSD).
262 *Rh5* prediction was unable to meet this threshold, therefore we proceeded with the most complete solved
263 structure of *Rh5* available. *AMA1* structures were missing domain III, as well as missing resolution of
264 many residues in a loop of domain II (residues 351–389). AlphaFold2 was able to confidently predict
265 domain III and the overall structure (RMSD 0.36), but the missing loop residues of domain II were of low
266 confidence, and the placement of the loop disagreed with the resolved residues of this loop in solved

267 structures. For this reason, we proceeded with an AlphaFold2 model of *AMA1* including domain III but
268 excluding the low confidence loop region of domain II.

269 *Pfs47* had no deposited structures. Hence, it was predicted entirely with AlphaFold2 with good confidence
270 (Fig. S3). *CelTOS* had no deposited structures for *P. falciparum*, but the *P. vivax* homolog has been
271 experimentally solved. We assessed a structure modeled with AlphaFold2 for *P. falciparum* *CelTOS* and
272 verified its fit to *P. vivax* (RMSD 1.59), trimming off residues outside the solved *P. vivax* structure.

273 AlphaFold2 structures were predicted on 3D7 reference sequences, utilizing the ColabFold⁶⁹
274 pipeline (<https://colab.research.google.com/github/sokrypton/ColabFold>). Multiple sequence alignments
275 were performed with MMseqs2 searching through UniRef+Environmental datasets. For each protein,
276 three different structure models were run with six recycles and early stops at 100 PLDDT. Templates and
277 AMBER relaxation were set to “off”. Models of rank one were chosen as final structures. For predicted
278 structures with solved references that needed loop or domain modeling, an agreement between predicted
279 and solved reference of 2 Å RMSD or less was deemed suitable for downstream analysis. For predicted
280 structures with no solved reference, a convergence of three models to a structure within 2 Å RMSD
281 between three models was assessed as a confident prediction model.

282 All the available solved antibody-antigen structures of seven of ten vaccine target proteins were
283 obtained from RCSB (as of 7/12/23). Using a custom R script, we extracted interface residues between
284 the antibody and target protein that occur within 5 Å of each other. *Pfs47* lacks antibody-antigen
285 structures, so we have included a known linear epitope (see Table 1). These interface residues were
286 sorted into bins for visualization purposes at 0, 1, 2, or 3+ antibody interfaces, to represent common
287 epitopes vs. infrequent and non-targeted residues. We consolidated identical antibodies with multiple
288 structures into a single record. This ensures that the count of epitopes involving each interface residue
289 only includes unique antibody contacts.

290

291 **Calculation of 3D population genetics measures**

292 To calculate spatially derived nucleotide diversity (π^*) and Tajima’s D (D^*) values, we utilized the
293 BiostructMap Python^{70,71} package, installed from <https://github.com/andrewguy/biostructmap>. The
294 package provides a method for mapping DNA sequence data to residues on protein structures, defining a

295 spatial neighborhood of the residue, and calculating the statistics using a three-dimensional (3D) sliding
296 window approach. In our study, we selected a 3D window with a radius of 15 Å, which represents the
297 maximum surface of an antibody-antigen binding site⁷². We chose not to apply a relative solvent
298 accessibility (RSA) filter and included all the residues within the radius of 15 Å, because polymorphisms
299 at buried residues could have structural effects on an epitope, and thus should be reflected in calculated
300 diversity and selection pressure.

301

302 **Role of the Funding Sources**

303 The funders of the study had no role in the study design, data collection, data analysis, data
304 interpretation, writing of the manuscript, or the decision to submit for publication.

305 **Results**

306 **Enhancing *P. falciparum* genomic diversity from African countries**

307 We augmented 241 *P. falciparum* whole genome sequences previously reported⁴³ with an additional 84
308 genomes from Zambia, a malaria endemic country in South-Central Africa currently lacking *P. falciparum*
309 genomic representation in public databases. Combining these data with publicly available WGS
310 sequences from the MalariaGEN *P. falciparum* Community Project Consortium⁷³
311 (<http://www.malariagen.net/resource/16>), WGS data of 1248 *P. falciparum* samples from 6 African
312 countries were processed to obtain gene sequence haplotypes for ten antigens, with the final data set
313 consisting of 1092 samples after quality filtering (Table 1, Table 2) for population genetic analyses. To
314 ensure high-quality haplotype reconstruction, the multiplicity of infections (MOI) was determined using
315 F_{ws} ⁵⁴, and samples with a high multiplicity of infections (MOI>2) were removed. Overall, 44.2% (483) of
316 1092 African field samples were found to harbor more than two infections, with Malawi having the highest
317 percentage (50.8%), followed by Zambia (48.9%) (Fig. S2). Moreover, 17.6% of samples (192) had
318 MOI=2 and 38.2% (417) were characterized as MOI=1 (Fig. S2). Additionally, there was a mean of 457
319 (range:196-579) sequences per antigen when considering full-length genes for analysis, and a mean of

320 591 (range: 555-623) sequences per antigen when considering partial genes for those with specific
321 regions of interest related to vaccine targets (Table 2).

322

323 **Antigen haplotypes lack geographic structure**

324 To assess the genealogical relationships amongst sequence haplotypes obtained from our newly derived
325 Zambian sequences and those from other African countries, we used TCS network analysis for the ten
326 antigens. Full length genes, as well as known vaccine target regions, were examined and compared (Fig.
327 2 and 3). In general, haplotypes did not exhibit clustering, irrespective of vaccine antigen type and
328 geographic origin. This observation held true whether the analysis considered the entire gene or specific
329 functionally relevant domains, suggesting a lack of geographic structure. (Fig. 2 and 3).

330 We identified the following percent of unique haplotypes across all countries for individual full-length
331 genes: 41.2% (100/243) for *CSP*, 62.5% (362/579) for *AMA1*, 6.8% (28/413) for *Rh5*, 89.3% (175/196) for
332 *MSP1*, 0.9% (5/552) for *Pfs25*, 4.5% (24/539) for *Pfs48/45*, 89.1% (383/430) for *Pfs230*, 12.3% (64/522)
333 for *Pfs47*, 4.7% (25/531) for *Pfs28*, and 33.9% (190/560) for *CeITOS*. For certain genes, we examined
334 specific regions of interest related to vaccine targets and identified the following percent of unique
335 haplotypes across all countries: 17.2% (107/623) for *CSP* C-terminal, 52.8% (308/583) for *AMA1*
336 (Domains I-III), 2.8% (17/612) for *MSP1* (C-terminal region: 19), 2.2% (12/562) for *Pfs48/45* (C-terminal 6-
337 Cys domain), 24.5% (149/609) for *Pfs230* (N-terminal prodomain and Domains I-III), and 1.4% (8/555) for
338 *Pfs47* (Del2). We further separated unique haplotypes by country for each gene (see Table 2 for full
339 diversity statistics results breakdown). To contextualize this specifically for Zambia, when considering
340 unique haplotypes solely from this country, we observed a modest number across all genes: 44.3%
341 (31/70) for *CSP* full-length and 26.5% (18/68) for *CSP* partial, 20.6% (65/315) for *AMA1* full-length and
342 20.2% (50/248) for *AMA1* partial, 18.8% (3/16) for *Rh5* full-length, 29.5% (51/173) for *MSP1* full-length
343 and 25% (1/4) for *MSP1* partial, 33.3% (1/3) for *Pfs25* full-length, 25% (4/16) for *Pfs48/45* full-length and
344 28.6% (2/7) for *Pfs48/45* partial, 22.6% (86/381) for *Pfs230* full-length and 17.2% (20/116) for *Pfs230*
345 partial, 15.8% (6/38) for *Pfs47* full-length and 25% (1/4) for *Pfs47* partial, 23.8% (5/21) for *Pfs28* full-
346 length, and 24.4% (32/131) for *CeITOS* full-length. The 3D7 vaccine strain haplotype was dominant for
347 antigens *Pfs48/45* (full-length and partial), and *Pfs25* and *Pfs28* (both full-length) (Fig. 3). In contrast, for

348 the more diverse antigens i.e., *Pfs230*, *AMA1*, *CSP* and *MSP1*, the 3D7 vaccine strain haplotype was
349 found at very low frequencies (Fig. 2 and 3).

350

351 **Differing signals of selection, haplotype, and nucleotide diversity across antigen types for vaccine** 352 **development considerations**

353 To understand haplotype diversity and investigate evidence of selection, we derived Nei's nucleotide
354 diversity (π), haplotype diversity (H_d) and *Tajima's D* statistics for each antigen. When taking full-length
355 genes into consideration, overall, five antigens, *Pfs230*, *AMA1*, *CSP*, *MSP1*, and *CeITOS*, representing
356 genes across the three categories of vaccine targets, exhibited the highest values of haplotype diversity
357 ($H_d > 0.9$) across all parasite populations analyzed (Fig. 4a, Table 2). Two transmission-blocking antigens,
358 *Pfs47* (0.85) and *Pfs48/45* (0.73) showed a moderate-high level of haplotype diversity, with similar levels
359 as those demonstrated by the blood-stage antigen *Rh5* (0.72) (Fig 4a, Table 2). The transmission-
360 blocking antigen *Pfs28* exhibited low haplotype diversity (0.29), and the lowest haplotype diversity was
361 observed for another transmission-blocking antigen, *Pfs25* (0.03) (Fig. 4a, Table 2). When considering
362 antigens with specific regions of interest for vaccine development, the same trend was observed: *AMA1*,
363 *CSP*, and *Pfs230* showed extremely high levels of haplotype diversity (0.99, 0.96, and 0.94, respectively),
364 followed by *MSP1* with high haplotype diversity (0.77), while *Pfs48/45* had moderate haplotype diversity
365 (0.43), and finally followed by *Pfs47* with the lowest haplotype diversity (0.35) (Fig. 4a, Table 2).

366 Furthermore, across the parasite populations, when examining all of the full-length genes, we detected
367 the highest levels of nucleotide diversity for *CeITOS* (0.0144) and *AMA1* (0.0137) (Fig. 4b, Table 2). The
368 next highest levels of nucleotide diversity were shown for *CSP* (0.0067), *MSP1* (0.0033), and this was
369 followed by similar levels observed for *Pfs47* (0.0015), *Pfs230* (0.0012), and *Pfs48/45* (0.0011) (Fig. 4b,
370 Table 2). These values were tenfold higher than the nucleotide diversity observed for genes *Rh5* and
371 *Pfs28* (0.0009 and 0.0005, respectively, and one hundred-fold lower than the nucleotide diversity
372 observed for *Pfs25* of 0.00001 (Fig. 4b, Table 2). When considering partial regions of interest for vaccine
373 development for the included genes, a similar pattern was observed; namely, *CSP* and *AMA1* had the
374 highest nucleotide diversity (0.016 and 0.014, respectively), while *MSP1*, *Pfs47*, and *Pfs230* had tenfold
375 lower nucleotide diversity (0.0057, 0.0024, and 0.0012), and *Pfs48/45* had the lowest recorded nucleotide

376 diversity of 0.0011 among the genes for which partial regions were studied (Fig. 4b, Table 2). When
377 examining specimens from Zambia alone, haplotype and nucleotide diversity aligned with the observed
378 ranges in the parasite populations across the three categories of vaccine targets.

379 To assess SNP neutrality across genes, we conducted *Tajima's D* statistical test, comparing average
380 pairwise differences between samples and the total number of segregating sites (Fig. 4c, Table 2).

381 *Tajima's D* values of 0 indicate neutrality in constant-size populations, negative values suggest purifying
382 selection, and positive values suggest balancing selection. When examining full-length antigens, *AMA1*
383 showed the strongest signature of balancing selection, with *Ce/TOS* displaying neutrality and weaker
384 signs of balancing selection, *CSP* exhibiting neutrality with signs of purifying selection, and *MSP1*
385 similarly showing neutrality with signs of purifying selection (Fig. 4c, Table 2). Conversely, *Pfs28*, *Pfs230*,
386 *Pfs47*, *Pfs25*, *Rh5*, *Pfs48/45* (in decreasing order) showed clear signatures of purifying selection (Fig. 4c,
387 Table 2). When inspecting antigens with partial regions of interest for vaccine development, we found that
388 *AMA1* still demonstrated strong balancing selection, while *MSP1* and *CSP* showed moderate signs of
389 balancing selection, contrasting with the full-length gene signatures (Fig. 4c, Table 2). On the other side
390 of the spectrum, *Pfs230* and *Pfs48/45* showed strong signs of purifying selection, while *Pfs47* displayed
391 neutrality with moderate levels of purifying selection (Fig. 4c, Table 2). Overall, there was no clear
392 correlation between balancing selection signals with vaccine target type, although a general pattern was
393 observed with the sexual stage antigens mostly showing evidence of purifying selection.

394

395 **Protein structures and balancing selection on known epitopes confirm transmission-blocking** 396 **antigens are not under immune selection**

397 To facilitate the search for effective malaria vaccine targets, we applied three structure-based analyses to
398 the structures of ten vaccine candidate proteins (Table 1): nucleotide diversity of a focal residue's spatial
399 neighborhood (π^*), *Tajima's D* of a focal residue's spatial neighborhood (D^*), and summarization of
400 experimentally solved antibody-antigen structures (Fig. 5). We then explored if there was a high
401 concentration of sequence diversity and balancing selection signatures within certain domains or patches
402 of each protein. Additionally, we sought to determine if these regions correlated with known epitopes.

403 The 3D nucleotide diversity, π^* , of *CSP*, *AMA1*, *CeITOS*, and *MSP1₁₉* showed the overall extreme
404 diversity of the molecules, which agrees with the 2D analysis. The 3D selection measure, D^* , however,
405 had greater variability across the molecules. *CSP* C-terminal domain exhibited uniformly high diversity and
406 selection, with 95% of spatial windows in regions of $\pi^* \geq 0.01$ (maximum $\pi^* = 0.046$), and 85% and 23%
407 of spatial windows under moderate to strong balancing ($D^* \geq 1$) and strong balancing selection ($D^* \geq 2$,
408 maximum $D^* = 3.34$) respectively. The structurally characterized epitopes had similar diversity and
409 selection pressures as the full *CSP* C-terminal domain (Fig. S4). The D^* , however, could be artificially
410 inflated for parts of the surface, including the conserved β -sheet epitope⁷⁴. Due to the small size of *CSP*
411 C-terminal domain, the 15Å spatial window implemented in biostructmap could include occluded residues
412 on the opposite surface with high polymorphism.

413 The known epitope of *AMA1*, structurally characterized from antibody 1F9⁷⁵ displayed higher diversity
414 and stronger selection signature than the full *AMA1* structure. Overall, *AMA1* was found to have 58% of
415 spatial windows in regions of $\pi^* \geq 0.01$ (maximum $\pi^* = 0.058$), and 67% were under moderate to strong
416 balancing selection (maximum $D^* = 3.38$), while the epitope of 1F9 shows 100% of their spatial windows
417 in regions of high diversity and high selection. Additionally, we recovered the signature of *AMA1*
418 displaying a distinctive side of the surface with heightened selection, and another side with no selection,
419 termed the “silent face” of *AMA1*^{76,77} (Fig. 5).

420 *CeITOS* showed a distinctive region of low diversity and selection corresponding to its inferred
421 dimerization interface⁷⁸ (Fig. 5). The overall structure of *CeITOS* was found to have 66% of spatial
422 windows with $\pi^* \geq 0.01$ (maximum $\pi^* = 0.041$), and 55% of spatial windows under moderate to strong
423 balancing selection (maximum $D^* = 2.01$) (Fig. S4).

424 *MSP1₁₉*, *Pfs48/45*, and *Rh5* contained regions under moderate balancing selection (D^* between 1-2).
425 *MSP1₁₉* domain 1 displayed stronger selection (mean $D^* = 0.67$) than domain 2 (mean $D^* = 0.34$). Among
426 the antibodies with characterized structures, 42D6 is the most potent and targets domains 1 and 2 at the
427 same time⁷⁹. One region in *Rh5* was found to be under selection, which is near its *Basigin* binding
428 interface⁸⁰. Interestingly, this region was shown to be targeted by infection-blocking antibodies⁸⁰⁻⁸². For
429 *Pfs48/45*, we found heightened diversity in domains 2 and 3 compared to domain 1, both of which are

430 binding sites of infection-blocking antibodies⁸³. Only part of domain 2 was found to be under moderate
431 balancing selection. Interestingly, none of the known epitopes overlap with the selected region.

432 Among the remaining four vaccine-candidate proteins encompassing the transmission-blocking
433 vaccine class, two had regions under weak balancing selection ($0 \leq D^* < 1$): *Pfs230* (maximum $D^* = 0.66$)
434 and *Pfs47* (maximum $D^* = 0.75$), and two, *Pfs25* and *Pfs28*, were found to be entirely under purifying
435 selection ($D^* \leq 0$) with maximum D^* of (-0.79) and (-0.78), respectively (Fig. S4).

436 Discussion

437 An ideal malaria vaccine target would be conserved with low balancing selection and containing
438 infection/transmission blocking epitopes that induce strain-transcending antibodies. Against these criteria,
439 ten malaria vaccine antigens targeting sporozoite (n=1), merozoite (n=3) and sexual lifecycle stages
440 (n=6), were assessed against newly generated Zambian parasite genomes, together with publicly
441 available *P. falciparum* WGS spanning five other countries in Africa.

442 The frequency of unique haplotypes varied across merozoite antigens when considering their full
443 lengths, ranging from a high of 89.3% for *MSP1* to a low of 6.8% for *Rh5*. Notably, transmission-blocking
444 antigens, including *Pfs25*, *Pfs48/45*, *Pfs28*, and *Pfs47*, exhibited markedly lower frequencies of unique
445 haplotypes (ranging from 0.9% to 12.3%) compared to the merozoite antigen *AMA1* (62.5%) and the pre-
446 erythrocytic antigen *CSP* (41.2%). *Pfs230*, another transmission-blocking antigen, demonstrated a
447 frequency of unique haplotypes similar to the highest recorded, *MSP1* (88%). The high number of
448 haplotypes is expected due to the length of the protein (>3100 AAs and 14 domains) and many
449 haplotypes are the result of rare polymorphisms²⁵. *CeITOS*, another sexual stage antigen studied,
450 displayed a moderate frequency of unique haplotypes at 33.9%. When focusing on specific regions
451 targeted for vaccine development, the merozoite antigen *AMA1* (Domains I-III) exhibited the highest
452 frequency of unique haplotypes (52.8%). In contrast, other antigens displayed lower frequencies: *Pfs230*
453 (N-terminal prodomain and Domains I-III) at 24.5%, *CSP* (C-terminal) at 17.2%, *Pfs47* (Del2) at 6.1%,
454 *MSP1* (C-terminal region: 19) at 2.8%, and *Pfs48/45* (C-terminal 6-Cys domain) at 2.1%. These findings
455 suggest a lack of a strict pattern based on vaccine types, although transmission-blocking antigens

456 generally exhibited lower frequencies of unique haplotypes compared to other vaccine antigens.
457 Additionally, the observed low frequency unique haplotypes may be attributed to the high malaria
458 transmission intensity in these regions of Africa.

459 Antibodies with varying effectiveness have been structurally characterized for seven of ten antigens
460 (see Table 1). Our genetic and structural analyses show that the human immune system plays an
461 important role in shaping the haplotype and nucleotide diversity of *P. falciparum* antigens, thus influencing
462 the potency and coverage of the antibodies. Based on the results, we identified five transmission-blocking
463 antigens (*Pfs28*, *Pfs25*, *Pfs48/45*, *Pfs47*, and *Pfs230*) and one blood-stage antigen (*Rh5*) as promising
464 candidates for developing broad-coverage vaccines. *Pfs28* and *Pfs25* demonstrate markedly lower
465 haplotype and nucleotide diversity than other antigens (Table 2; see also ^{40,84}) because they are not
466 expressed within human hosts and therefore they are not subjected to immune selection^{85,86}. The
467 drawback of no natural exposure to the human immune system from these two antigens is the lack of
468 antibody-boosting effect upon subsequent natural infections. Nevertheless, the low diversity and no signs
469 of selection warrant *Pfs28* and *Pfs25* as promising potential broad-coverage transmission blocking
470 vaccines. Additionally, combining antibodies raised to these antigens results in synergistic transmission
471 blocking activity, highlighting the possibility of a multi-component vaccine using *Pfs25* and *Pfs28*⁸⁶. Other
472 transmission-blocking (sexual stage) antigens, such as *Pfs48/45*, *Pfs47*, and *Pfs230*, also represent
473 promising broad-coverage vaccine candidates, with the added advantage of antibody-boosting upon
474 subsequent exposure, and synergistic transmission blocking activity when combining antibodies of
475 *Pfs48/45* and *Pfs230*⁸⁷. In addition, despite brief exposure to the immune system during merozoite
476 invasion⁸⁸, *Rh5* seems to be a more promising immunogen due to a less diverse haplotype population
477 and potent antibodies with cross-reactivity^{80,81}.

478 For the pre-erythrocytic antigen, *CSP* C-terminal domain was shown to be highly polymorphic in
479 the current study [Fig. 5; see also ⁷⁴]. Notably, the 3D7 haplotype of *CSP* C-terminal domain represents
480 only 3.7% of haplotypes circulating in our study (Fig. 2 and ²⁹). Earlier studies have shown that 3D7
481 haplotype-based RTS,S vaccine efficacy decreases with increased mutational distance from the 3D7
482 haplotype³³. *CSP* C-terminal domain has two characterized B-cell epitopes, and both are capable of weak
483 inhibition of hepatocyte invasion⁷⁴. One overlaps with T-cell epitopes Th2R and Th3R and contains many

484 polymorphic residues, which limits the cross-reactivity of antibodies to other *P. falciparum* strains^{74,89}. A
485 second epitope on a conserved β -sheet of CSP C-terminal domain was shown to have broad cross-
486 reactivity⁷⁴ but much weaker invasion inhibition than antibodies targeting NANP repeats^{74,90}. Overall, the
487 C-terminal domain of CSP might not be sufficient to elicit full protection for the entire parasite population,
488 namely in generating broad cross-reactive antibodies capable of potent inhibition of infection.

489 The blood-stage antigens, *AMA1* (Domains I-III) and *MSP1₁₉*, are more diverse than the
490 transmission-blocking antigens, with a significant portion of their surface under at least moderate
491 balancing selection (Fig. 5). These results are consistent with previous studies investigating across Africa
492 and globally, with work revealing balancing selection and high haplotype diversity^{25,39,91}. Additionally, the
493 3D7 haplotype was not dominant for these antigens (Fig. 2). Many polymorphic residues in *AMA1* 1F9's
494 epitope found in our study were shown to abrogate 1F9 binding (H 200 [E,R,L,V], D 204 [K,N], I 225
495 [N])⁷⁵, implying that a single vaccine is unlikely to confer protection to multiple divergent haplotypes that
496 exist in natural parasite populations. Not included in the present structural analysis is a highly flexible loop
497 of D2, which has a conserved epitope (targeted by 4G2 monoclonal antibody⁹²). Among the antibodies
498 with characterized structures for *MSP1₁₉*, 42D6 is reported to be the most potent and targets domain 1
499 and 2 simultaneously⁷⁹. We found three polymorphic residues in the epitope of 42D6, two of which (Pf3D7
500 E1671K, L1692F) have been confirmed not to significantly impact binding, while the effect on binding and
501 potency of the third residue (Pf3D7 G1623R) remains uncharacterized and thus unknown. In contrast,
502 *Rh5* is uniquely well-conserved among blood-stage antigens, as previously reported⁹³. Most potent
503 antibodies to *Rh5* were found around the binding interface of *Rh5* and human protein *Basigin*⁸¹. These
504 antibodies often target patches with no polymorphisms in our data with one exception (Pf3D7 C203Y),
505 which has been shown to not affect binding⁸¹. Other epitope regions near *Rh5*'s interface with *PfCyRPA*
506 were not effective in blocking merozoite invasion⁸². Therefore, targeting the *Rh5-Basigin* interface has the
507 potential as an effective vaccine against merozoite invasion.

508 For transmission-blocking antigens, *Pfs47* was previously shown to be non-essential for *P.*
509 *falciparum* life cycle, as mutants lacking this protein were capable of normal fertilization⁹⁴. In contrast,
510 both *Pfs48/45* and *Pfs230* are essential antigens for *P. falciparum* life cycle^{95,96}. Potent transmission-
511 blocking antibodies have been characterized for *Pfs48/45*^{83,97,98}, *Pfs230* (*D1*, *D2*)⁹⁹⁻¹⁰¹, and *Pfs47*¹⁰². As

512 reported above, we only found signals of weak or no balancing selection in these three antigens where
513 potent antibodies are binding. Polymorphic residues on domain 3 of *Pfs48/45* in our dataset were found
514 not to affect binding affinity severely and the antibodies retained nanomolar affinity ranges⁹⁷. In *Pfs230*,
515 some of the potent transmission-blocking antibodies raised from natural exposure bound to regions with
516 no polymorphism in our study¹⁰⁰, while other potent antibodies raised from human vaccine trials bound to
517 polymorphic regions¹⁰¹. Among the polymorphic sites, (Pf3D7 G605S, D714N) were shown to affect
518 binding, while (Pf3D7 E654K, E655V, and A699T) did not. The remaining set of polymorphic residues
519 (Pf3D7 N616K, T656N, V727I) segregate at low frequencies and have not been tested for changes in
520 binding affinities. *Pfs47* also contained polymorphic residues in the epitope of a potent antibody¹⁰².
521 However, the influence of these polymorphisms has not been characterized. Immunization to both *Pfs28*
522 and *Pfs25* have been shown to raise potent transmission-blocking antibodies^{86,103-112}. The impact of
523 polymorphic residues (Pf3D7 L63V, V132I) of *Pfs25* on the binding affinities of the antibodies has not yet
524 been characterized.

525 While a part of transmission-blocking antigens, *CeITOS* is critical to liver invasion by sporozoites
526 during the pre-erythrocytic stage⁷⁸. The heightened balancing selection pressure and nucleotide diversity
527 of *CeITOS* compared to the other transmission-blocking target antigens reflects its intense interaction with
528 the human immune system. While no antibodies have been structurally characterized against *CeITOS* at
529 the time of this study, it has been shown that mice immunized with *CeITOS* can raise potent transmission-
530 blocking antibodies¹¹³. However, with nearly the entire surface exposed regions of *CeITOS* under
531 moderate balancing selection, it is unlikely to provide broad-coverage vaccinations.

532 We acknowledge that this study is not without limitations. Firstly, it was a secondary analysis of a
533 broader study⁴³, and we did not intend to do an exhaustive study of all vaccine candidate genes. We
534 chose to incorporate representative genes across the three classes of vaccine candidates with a focus on
535 transmission-blocking antigens that are currently under clinical vaccine development. Identifying potential
536 vaccine targets from the proteome is beyond our study scope. Secondly, our study used samples mainly
537 from sub-Saharan Africa with a particular focus on Zambia where genomic data were lacking. However,
538 we acknowledge the absence of representation from Asia or South America. While we recognize that a
539 study with a globally representative set of samples would be more comprehensive, we believe that this

540 investigation is still useful for understanding vaccine development in the context of Africa and Zambia
541 specifically, a country that remains highly malaria endemic. Lastly, the analyses of full-length and partial
542 genes should not be directly compared as they incorporated varying numbers of samples (the partial
543 genes typically included more samples than the full-length genes). The partial gene analyses for regions
544 of interest and the corresponding 3D structural analyses are more relevant for informing vaccine
545 development.

546 In conclusion, this study offers valuable insights into selecting *P. falciparum* vaccine antigens with regions
547 under low balancing selection and the presence of infection/transmission-blocking epitopes, which are
548 essential for informing the development of new malaria vaccines. Based on these findings, we
549 recommend the following strategies for vaccine design: 1) a multi-stage vaccine encompassing anti-
550 merozoite (*Rh5*) and transmission-blocking antigens (*Pfs25*, *Pfs28*, *Pfs48/45*, *Pfs230*), and 2)
551 transmission-blocking vaccines targeting combinations of *Pfs25*, *Pfs28*, and *Pfs48/45*. These approaches
552 hold promise for the development of more effective malaria vaccines in the future.

553

554 **Contributors**

555 I.I.C, Q.H. and G.C. conceived and designed the study. I.I.C, B.K.B, S.X., Q.H and G.C. generated and
556 collected data. S.X., I.I.C., B.K.B., Q.H., and G.C. analyzed data and interpret results. J.T., Q.H. and G.C.
557 supervised analysis. M.C.M., B.M., C.M., J.M., J.L.S. W.J.M., and D.J.B. contributed to
558 samples/materials. I.I.C., B.K.B., Q.H., and G.C wrote the manuscript. All authors read, edited, and
559 approved the manuscript for publication.

560

561 **Declaration of interests**

562 All authors declare no competing interests.

563

564 **Data Sharing**

565 The raw sequence data are available in the NCBI Sequence Read Archive under BioProject
566 PRJNA932927. Key analysis scripts can be accessed at https://github.com/giocarpi/Pf_capture_div_code.

567

568 **Acknowledgements**

569 We would like to thank collaborators at the Zambia National Malaria Elimination Centre, the study
570 participants, and the Southern and Central Africa International Centers of Excellence for Malaria
571 Research (ICEMR). We would also like to extend our gratitude to the communities and researchers of
572 malaria endemic countries that enabled the collection and availability of the *P. falciparum* genomes used
573 in this study and made publicly available through the MalariaGEN *P. falciparum* Community. The authors
574 would also like to thank Abebe Fola for his contributions in extracting genomic DNA from DBS samples.

575

576 **Additional information**

577 **Correspondence** should be addressed to Giovanna Carpi and Qixin He.

578

579

580

581

582

583

584

585

586


587

588

589


590

591 Figures and Tables



592
593 **Figure 1. *Plasmodium falciparum* life cycle in the *Anopheles* mosquito vector and human host and**
594 **corresponding targets for malaria vaccine development.**


595 Vaccine strategies are broadly grouped by the *P. falciparum* life stage they target and include the
596 categories: pre-erythrocytic, blood stage, and transmission-blocking. The pre-erythrocytic class of
597 vaccines usually include candidates that target sporozoites or infected hepatocytes to prevent clinical
598 initial infection and stop malaria parasites from re-entering the bloodstream. The blood stage vaccines
599 target the parasite during replication in red blood cells in the human. Lastly, transmission-blocking
600 vaccines target sexual and/or sporogonic development stages and aim to induce antibodies in humans
601 that impair the parasite's development inside the mosquito midgut and thus subsequently prevent the
602 transmission of sporozoites to humans. The antigens shown in bold were included in this study.



603

604

605 **Figure 2. Haplotype network for malaria vaccine antigens (pre-erythrocytic and blood-stage**
606 **proteins).** Templeton, Crandall, and Sing (TCS) networks illustrate the diversity of the selected antigens.
607 Circles represent unique nucleotide haplotypes and are scaled according to the frequency with which the
608 haplotype was observed. The number of mutation differences that exist between each haplotype is
609 depicted by the number of hatch marks on the network branches. Haplotype colors match the geographic
610 origin of the samples depicted on the map (see map legend). The vaccine strain 3D7 (grey color,
611 surrounded by a red box) is included for reference in each respective haplotype network.
612



613

614

615 **Figure 3. Haplotype network for malaria vaccine antigens (transmission-blocking proteins).**

616 Templeton, Crandall, and Sing (TCS) networks illustrate the diversity of the selected antigens. Circles
617 represent unique nucleotide haplotypes and are scaled according to the frequency with which the
618 haplotype was observed. The number of mutation differences that exist between each haplotype is
619 depicted by the number of hatch marks on the network branches. Haplotype colors match the geographic
620 origin of the samples depicted on the map (see map legend). The vaccine strain 3D7 (grey color,
621 surrounded by a red box) is included for reference in each respective haplotype network.

622

623

624

625

626

627

628

629

630

631

632


633

634

635

636

637



638

639 **Figure 4. Results of haplotype diversity, nucleotide diversity, and Tajima's D values for each**
640 **antigen across all countries included in this study.** The horizontal barplot depicts the calculated
641 values for the specified diversity parameters for each antigen across the different parasite populations.
642 Three diversity parameters were included: haplotype diversity (panel a) and nucleotide diversity (panel b)
643 (calculated using DNAsp), and Tajima's D statistic (panel c) (calculated using MEGA). Colors are selected
644 to show the lifecycle stage of the parasite of the respective antigen (see legend for specific colors) and
645 also correspond to the colors depicted in Fig. 1 of the *P. falciparum* parasite life cycle stages. The fully
646 shaded-in bars indicate full-length genes, while the dashed bars denote partial length genes for genes
647 with specific regions of interest for vaccine development.


648

649

650

651

652



653

654 **Figure 5. Vaccine candidate structural analyses of nucleotide diversity (π^*), Tajima's D^* , and**

655 **antibody-antigen interactions (epitopes).** A 3D sliding window of 15 Å was used for all calculations.

656 Residues with no nearby SNP mapping residues are colored grey. Nucleotide diversity (π^*) uses a log

657 scale from extremely low diversity (10^{-5}) to extremely high diversity (10^{-1}). Tajima's D^* varies from no

658 balancing selection (<0) to strong balancing selection (>2) on a linear scale. In the column of known

659 epitopes, the discrete color scale indicates the number of times a residue was part of an antibody-antigen

660 structure deposited in RCSB. This column is additionally annotated with relevant domain, epitope, and

661 protein-protein interaction surfaces.

662 **Table 1. Vaccine candidate antigens.**

663 *P. falciparum* antigens included in this study, with respective type of vaccine, lifecycle stage, full or partial
 664 gene used in analyses from NCBI gene database, and 3-D structure reference and antibody-antigen
 665 structures used in analyses from Research Collaboratory for Structural Bioinformatics (RCSB) database.
 666 The gene information of the proteins is provided in Table S1. All are relevant key candidates from malaria
 667 vaccine trials and are functionally important for malaria biology as they target different stages of the
 668 *Plasmodium falciparum* life cycle (See Figure 1). AF2 represents AlphaFold solved structures. “→”
 669 indicates we used AlphaFold to resolve loop regions instead of the solved structure (see Methods for
 670 details).

671

Type of vaccine (Parasite lifecycle stage)	Protein Name	Analysis (full/partial gene), [nt]	Structure reference	AA start – AA end	Antibody-Antigen structures
Pre-erythrocytic (sporozoite)	<i>CSP</i>	full-length, partial (C-terminal), [829-1194]	7rxp ⁽⁷⁴⁾	309 – 373	6b0s ⁽⁸⁹⁾ , [7rxj, 7rxj, 7rxl, 7rxp, 7s0x] ⁽⁷⁴⁾
Blood-stage (merozoite)	<i>AMA1</i>	partial (Domains I-III), [298-1635]	2q8a ⁽⁷⁵⁾	107 – 438	[2q8a, 2q8b] ⁽⁷⁵⁾
	<i>Rh5</i>	full-length	4wat ⁽¹¹⁴⁾	146 – 513	[4u0r, 4u1g] ⁽⁸⁰⁾ , 5mi0 ⁽¹¹⁵⁾ , [6rcu, 6rcv] ⁽⁸¹⁾ , [7phu] ⁽⁸²⁾
	<i>MSP1</i>	partial (C-terminal region: 19), [4822-5097]	8dfh --> AF2	1608 - 1699	[8dfh, 8dfi, 8dfg] ⁽⁷⁹⁾ , 1ob1 ⁽¹¹⁶⁾ , 6xqw ⁽¹¹⁷⁾
Transmission-blocking (sexual and/or	<i>Pfs25</i>	full-length	6b0e ⁽¹⁰⁷⁾ → AF2	23 – 193	[6azz, 6b0h, 6b0e, 6b08, 6b0a, 6b0g] ⁽¹⁰⁷⁾ , [6phb, 6phd, 6phf, 6phc] ⁽¹⁰⁸⁾ , 7txw ⁽¹¹⁸⁾

sporogonic development stages)	<i>Pfs48/45</i>	full-length, partial (C-terminal 6-Cys domain), [871-1284]	7zxcg ⁽⁸³⁾ → AF2	45 – 428	[7zwf, 7zwi, 7zxf, 7zwm, 7zxcg] ⁽⁸³⁾ , 6h5n ⁽⁸³⁾ , 7uxl ⁽⁹⁷⁾ , 7unb ⁽¹¹⁹⁾ , [6e63, 6e62] ⁽¹²⁰⁾
	<i>Pfs230</i>	full-length, partial (N-terminal prodomain + Domains I-III), [1327-3396]	7ufw ⁽¹⁰¹⁾ → AF2	552 - 890	6ohg ⁽⁸⁷⁾ , 7jum ⁽⁹⁹⁾ , [7uvi, 7uvq, 7uvs, 7uvo, 7uvh] ⁽¹⁰⁰⁾ , [7u9w, 7ua2, 7ufw, 7ua8, 7ubs, 7ucq, 7uc8, 7u9e, 7ui1] ⁽¹⁰¹⁾
	<i>Pfs47</i>	full-length, partial (Del2), [532-687]	None → AF2	22 – 419	Linear epitope (no structure solved) for amino acids 178-229 ⁽¹⁰²⁾
	<i>Pfs28</i>	full-length	8e1z ⁽¹²¹⁾	24 - 178	N/A
	<i>CelTOS</i>	full-length	(Pv) 5tsz ⁽⁷⁸⁾ --> AF2	35 - 164	N/A

672

673

674

675

676

677

678

679

680

681

682

683

684

685 **Table 2. Diversity Statistics Results.**

686 Summary of the samples from Africa included in our analyses per gene.

687 n=number of sequences, h=number of unique haplotypes, h_c=number of unique haplotypes from a

688 respective country alone, S=number of polymorphic (segregating) sites, k=average number of pairwise

689 nucleotide differences, Hd=haplotype (gene) diversity, π=nucleotide diversity, D=Tajima's neutrality test

690 statistic

691

Gene Name (Gene Symbol)	Country	n	h	h_c	S	k	Hd	π	D
(PF3D7_0304600) CSP, full	<i>All</i>	243	100	70	63	7.321	0.977	0.0067	-0.877
	DRC	25	17	7	33	8.140	0.923	0.0070	-0.258
	Ghana	51	34	12	30	6.921	0.976	0.0059	0.126
	Guinea	41	23	7	28	6.667	0.951	0.0058	0.064
	Malawi	32	18	4	29	7.486	0.958	0.0065	0.141
	Tanzania	20	16	9	27	7.147	0.974	0.0061	-0.237
	Zambia	74	50	31	50	8.061	0.985	0.0072	-0.703
(PF3D7_0304600) CSP, partial (C-terminal)	<i>All</i>	623	107	68	38	5.987	0.962	0.0164	0.277
	DRC	73	27	6	23	5.960	0.946	0.0163	0.797
	Ghana	138	44	18	28	5.685	0.953	0.0156	0.341
	Guinea	72	29	6	23	6.079	0.957	0.0166	0.865
	Malawi	125	40	12	26	5.757	0.964	0.0157	0.572
	Tanzania	50	23	8	24	5.783	0.951	0.0158	0.258
	Zambia	165	45	18	26	6.322	0.952	0.0173	1.080
(PF3D7_1133400) AMA1, full	<i>All</i>	579	362	315	114	25.550	0.997	0.0137	1.606
	DRC	70	60	50	82	25.598	0.993	0.0137	1.710
	Ghana	129	99	79	88	25.124	0.993	0.0134	1.762
	Guinea	71	60	45	85	24.690	0.992	0.0132	1.369
	Malawi	125	73	51	84	25.762	0.990	0.0138	2.101
	Tanzania	52	43	25	76	25.519	0.991	0.0137	1.812
	Zambia	132	89	65	87	25.635	0.987	0.0137	1.938
	<i>All</i>	583	308	248	84	21.319	0.995	0.0159	2.171

(PF3D7_1133400) AMA1, partial (Domains I-III)	DRC	71	54	36	64	21.384	0.985	0.0160	2.059
	Ghana	131	89	63	68	20.715	0.991	0.0155	2.080
	Guinea	71	59	39	70	21.041	0.992	0.0157	1.522
	Malawi	125	69	39	66	21.477	0.989	0.0161	2.395
	Tanzania	52	43	21	61	21.548	0.991	0.0161	2.069
	Zambia	133	82	50	70	21.454	0.985	0.0160	2.127
(PF3D7_0424100) Rh5, full	<i>All</i>	413	28	16	19	1.347	0.718	0.0009	-1.318
	DRC	28	7	2	7	1.013	0.624	0.0006	-1.312
	Ghana	112	12	4	9	0.692	0.530	0.0004	-1.456
	Guinea	66	9	0	6	0.814	0.616	0.0005	-0.854
	Malawi	116	10	1	7	1.637	0.785	0.0010	0.562
	Tanzania	41	14	6	11	1.715	0.790	0.0011	-1.006
(PF3D7_0930300) MSP1, full	<i>All</i>	196	175	173	118	16.510	0.999	0.0033	-0.565
	DRC	20	18	17	61	17.100	0.989	0.0034	-0.022
	Ghana	37	35	35	81	16.480	0.997	0.0033	-0.554
	Guinea	22	22	22	67	17.403	1.000	0.0035	-0.212
	Malawi	52	40	39	67	15.778	0.989	0.0031	0.223
	Tanzania	10	10	9	49	15.467	1.000	0.0031	-0.523
(PF3D7_0930300) MSP1, partial (C-terminal region: 19)	<i>All</i>	612	17	4	8	1.585	0.773	0.0057	0.752
	DRC	73	11	0	7	1.648	0.800	0.0060	0.357
	Ghana	139	9	0	6	1.571	0.729	0.0057	0.944
	Guinea	73	11	1	8	1.801	0.791	0.0065	0.241
	Malawi	124	12	1	7	1.613	0.782	0.0058	0.551
	Tanzania	49	9	1	7	1.480	0.751	0.0054	-0.153
(PF3D7_1031000) Pfs25, full	<i>All</i>	552	5	3	4	0.029	0.029	0.0000	-1.489
	DRC	67	1	0	0	0.000	0.000	0.0000	n/c
	Ghana	128	1	0	0	0.000	0.000	0.0000	n/c
	Guinea	67	1	0	0	0.000	0.000	0.0000	n/c
	Malawi	121	4	2	3	0.082	0.081	0.0001	-1.480
	Tanzania	47	2	0	1	0.043	0.043	0.0000	-1.109

	Zambia	122	3	1	2	0.033	0.033	0.0001	-1.351
(PF3D7_1346700)	<i>All</i>	539	24	16	19	1.433	0.734	0.0011	-1.168
Pfs48/45, full	DRC	65	9	3	6	1.242	0.648	0.0009	-0.043
	Ghana	128	13	6	9	1.151	0.691	0.0009	-0.738
	Guinea	65	8	2	6	0.912	0.633	0.0007	-0.676
	Malawi	117	8	1	6	1.394	0.668	0.0010	0.525
	Tanzania	49	6	0	3	1.350	0.687	0.0010	2.090
	Zambia	115	12	4	8	1.205	0.671	0.0009	-0.473
	(PF3D7_1346700)	<i>All</i>	562	12	7	11	0.452	0.429	0.0011
Pfs48/45, partial (C-terminal 6-Cys domain)	DRC	57	4	1	3	0.200	0.195	0.0005	-1.322
	Ghana	131	4	1	3	0.564	0.525	0.0014	0.042
	Guinea	67	5	2	4	0.594	0.544	0.0014	-0.621
	Malawi	118	4	1	3	0.299	0.292	0.0007	-0.814
	Tanzania	49	2	0	1	0.332	0.332	0.0008	0.647
	Zambia	130	7	2	6	0.225	0.215	0.0005	-1.718
	(PF3D7_0209000)	<i>All</i>	430	383	381	180	11.082	0.999	0.0012
Pfs230, full	DRC	50	47	47	64	11.440	0.998	0.0012	-0.697
	Ghana	85	83	83	89	11.085	0.999	0.0012	-1.251
	Guinea	57	55	54	72	10.936	0.999	0.0012	-1.035
	Malawi	103	77	75	75	9.224	0.995	0.0010	-1.166
	Tanzania	37	37	36	46	9.216	1.000	0.0010	-0.587
	Zambia	98	87	86	68	9.389	0.995	0.0010	-0.934
	(PF3D7_0209000)	<i>All</i>	609	149	116	53	2.452	0.944	0.0012
Pfs230, partial (N-terminal prodomain + Domains I-III)	DRC	68	34	15	23	2.575	0.953	0.0013	-1.438
	Ghana	134	64	39	29	2.897	0.963	0.0014	-1.330
	Guinea	74	38	21	18	2.702	0.964	0.0013	-0.796
	Malawi	129	37	11	18	2.079	0.916	0.0010	-1.029
	Tanzania	49	22	10	17	2.148	0.923	0.0010	-1.368
	Zambia	155	40	20	21	2.155	0.919	0.0011	-1.173
	(PF3D7_1346800)	<i>All</i>	522	64	38	33	2.022	0.850	0.0015
Pfs47, full	DRC	60	20	6	12	2.267	0.925	0.0017	-0.341
	Ghana	124	30	13	19	1.982	0.808	0.0015	-1.224
	Guinea	67	16	3	10	1.663	0.772	0.0013	-0.561

	Malawi	118	25	8	16	1.468	0.652	0.0011	-1.396
	Tanzania	46	14	2	11	1.837	0.812	0.0014	-0.787
	Zambia	107	22	6	13	1.623	0.741	0.0012	-0.922
(PF3D7_1346800)	<i>All</i>	555	8	4	7	0.380	0.354	0.0024	-1.184
Pfs47, partial (Del2)	DRC	66	4	0	3	0.626	0.565	0.0040	-0.015
	Ghana	132	5	1	4	0.461	0.419	0.0030	-0.703
	Guinea	69	5	1	4	0.394	0.370	0.0025	-1.119
	Malawi	121	5	1	4	0.160	0.142	0.0010	-1.509
	Tanzania	49	4	0	3	0.347	0.327	0.0022	-1.005
	Zambia	118	4	1	3	0.295	0.289	0.0019	-0.828
	(PF3D7_1030900)	<i>All</i>	531	25	21	23	0.313	0.291	0.0005
Pfs28, full	DRC	62	3	1	2	0.236	0.232	0.0004	-0.757
	Ghana	125	7	5	6	0.340	0.326	0.0005	-1.506
	Guinea	66	6	3	5	0.314	0.298	0.0005	-1.608
	Malawi	119	10	6	9	0.280	0.263	0.0004	-2.028
	Tanzania	46	5	1	4	0.215	0.207	0.0003	-1.764
	Zambia	113	8	5	7	0.386	0.338	0.0006	-1.628
	(PF3D7_1216600)	<i>All</i>	560	190	131	42	7.891	0.981	0.0144
Ce/TOS, full	DRC	68	40	15	28	7.026	0.965	0.0128	0.639
	Ghana	131	70	38	29	8.331	0.979	0.0152	1.663
	Guinea	66	42	13	28	7.998	0.973	0.0146	1.138
	Malawi	122	55	25	30	7.848	0.974	0.0143	1.210
	Tanzania	49	33	8	30	7.571	0.969	0.0138	0.418
	Zambia	124	65	32	37	7.659	0.978	0.0140	0.353

692

693

694

695

696 **Supplementary Material**




697
698 **Figure S1. Map of African endemic countries from which *P. falciparum* WGS were included in the**
699 **study.** Map showing the newly generated *P. falciparum* WGS from Zambia (outlined in black) and publicly
700 available WGS data from other malaria endemic countries (MalariaGEN Pf3K) (shown in dark grey).

701

702

703

704



705

706 **Figure S2. Characterization of multiplicity of infections estimated by *Fws* among 1092 *P.***

707 ***falciparum* genomes across 6 African countries.** Colored bars represent the proportion of samples


708 with different levels of multiplicity of infection in each country based on *Fws*. MOI=1: *Fws* above 0.95;

709 MOI=2, *Fws* between 0.8 and 0.95; MOI>2, *Fws* below 0.8.

710

711

712




713

714

715 **Figure S3. Vaccine candidates' AlphaFold2 model confidence.** The color scale represents
716 AlphaFold2's reported predicted local Distance Difference Test (pLDDT) for each structure model. See
717 methods for AlphaFold2 implementation. Text under protein names indicates reference structure models
718 and the agreement of alignments measured in Root Mean Squared Deviation (RMSD) over a certain
719 number of atoms.

720



721
 722 **Figure S4. Spatially derived nucleotide diversity and Tajima's D summaries for whole protein**
 723 **structures versus known epitope residues.** Known epitope residues, indicated as "epi: protein name",
 724 are calculated from solved antibody-antigen structures listed in Table 1. Color indicates the proportion of
 725 residues in each corresponding bin of nucleotide diversity. See methods for calculation of spatially
 726 derived statistics and calculation of epitope residues from solved structures. **A)** Summary of spatially
 727 derived nucleotide diversity (π^*) values for whole protein structures versus known epitope residues. **B)**
 728 Summary of spatially derived Tajima's D (D^*) values for whole protein structures versus known epitope
 729 residues.
 730
 731
 732

733 **Table S1. Gene information of vaccine candidate antigens.**

734 Chromosome number and coordinates, relevant gene symbol and IDs of *P. falciparum* antigens from

735 NCBI gene database.

Gene Name	Chromosome Number	Chromosome Coordinates	Gene Symbol	Gene ID
CSP	3	(221323..222516, complement)	PF3D7_0304600	814364
AMA1	11	(1293856..1295724)	PF3D7_1133400	810891
RH5	4	(1082363..1084150, complement)	PF3D7_0424100	812437
MSP1	9	(1201812..1206974)	PF3D7_0930300	813575
Pfs25	10	(1253417..1254070, complement)	PF3D7_1031000	810560
Pfs45/48	13	(1876016..1877362, complement)	PF3D7_1346700	814212
Pfs230	2	(370438..379845)	PF3D7_0209000	812682
Pfs47	13	(1878875..1880194, complement)	PF3D7_1346800	814213
Pfs28	10	(1251151..1251807, complement)	PF3D7_1030900	810459
CeITOS	12	(659738..660286, complement)	PF3D7_1216600	811213

736

737

738 References

- 739
- 740 1. Duffy PE, Sahu T, Akue A, Milman N, Anderson C. Pre-erythrocytic malaria vaccines:
741 identifying the targets. *Expert Review of Vaccines* 2012; **11**(10): 1261-80.
 - 742 2. Marques-da-Silva C, Peissig K, Kurup SP. Pre-Erythrocytic Vaccines against Malaria.
743 *Vaccines* 2020; **8**(3): 400.
 - 744 3. Duffy PE, Patrick Gorres J. Malaria vaccines since 2000: progress, priorities, products.
745 *npj Vaccines* 2020; **5**(1): 48.
 - 746 4. Molina-Franky J, Cuy-Chaparro L, Camargo A, et al. Plasmodium falciparum pre-
747 erythrocytic stage vaccine development. *Malaria Journal* 2020; **19**(1): 56.
 - 748 5. WHO. WHO recommends groundbreaking malaria vaccine for children at risk. 2021.
749 [https://www.who.int/news/item/06-10-2021-who-recommends-groundbreaking-malaria-vaccine-](https://www.who.int/news/item/06-10-2021-who-recommends-groundbreaking-malaria-vaccine-for-children-at-risk)
750 [for-children-at-risk](https://www.who.int/news/item/06-10-2021-who-recommends-groundbreaking-malaria-vaccine-for-children-at-risk) (accessed February 11 2023).
 - 751 6. Oxford. Oxford R21/Matrix-M™ malaria vaccine receives regulatory clearance for use in
752 Burkina Faso. 2023. [https://www.ox.ac.uk/news/2023-07-24-oxford-r21matrix-m-malaria-](https://www.ox.ac.uk/news/2023-07-24-oxford-r21matrix-m-malaria-vaccine-receives-regulatory-clearance-use-burkina-faso)
753 [vaccine-receives-regulatory-clearance-use-burkina-faso](https://www.ox.ac.uk/news/2023-07-24-oxford-r21matrix-m-malaria-vaccine-receives-regulatory-clearance-use-burkina-faso) (accessed September 9 2023).
 - 754 7. Friedman-Klabanoff DJ, Berry AA, Travassos MA, et al. Low dose recombinant full-
755 length circumsporozoite protein-based Plasmodium falciparum vaccine is well-tolerated and
756 highly immunogenic in phase 1 first-in-human clinical testing. *Vaccine* 2021; **39**(8): 1195-200.
 - 757 8. Miura K. Progress and prospects for blood-stage malaria vaccines. *Expert Review of*
758 *Vaccines* 2016; **15**(6): 765-81.
 - 759 9. Sauerwein RW, Bousema T. Transmission blocking malaria vaccines: Assays and
760 candidates in clinical development. *Vaccine* 2015; **33**(52): 7476-82.
 - 761 10. Coelho CH, Rappuoli R, Hotez PJ, Duffy PE. Transmission-Blocking Vaccines for
762 Malaria: Time to Talk about Vaccine Introduction. *Trends in Parasitology* 2019; **35**(7): 483-6.
 - 763 11. WHO. World malaria report 2022. 2022.
764 <https://www.who.int/publications/i/item/9789240064898> (accessed February 9 2023).
 - 765 12. Laurens MB. RTS,S/AS01 vaccine (Mosquirix™): an overview. *Hum Vaccin*
766 *Immunother* 2020; **16**(3): 480-9.
 - 767 13. Keating C. The history of the RTS,S/AS01 malaria vaccine trial. *The Lancet* 2020;
768 **395**(10233): 1336-7.
 - 769 14. WHO. WHO review of malaria vaccine clinical development. 2024.
770 [https://www.who.int/observatories/global-observatory-on-health-research-and-](https://www.who.int/observatories/global-observatory-on-health-research-and-development/monitoring/who-review-of-malaria-vaccine-clinical-development)
771 [development/monitoring/who-review-of-malaria-vaccine-clinical-development](https://www.who.int/observatories/global-observatory-on-health-research-and-development/monitoring/who-review-of-malaria-vaccine-clinical-development) (accessed
772 February 15 2024).
 - 773 15. Oxford. Oxford R21/Matrix-M™ malaria vaccine receives WHO recommendation for
774 use paving the way for global roll-out. 2023. [https://www.ox.ac.uk/news/2023-10-02-oxford-](https://www.ox.ac.uk/news/2023-10-02-oxford-r21matrix-m-malaria-vaccine-receives-who-recommendation-use-paving-way-global)
775 [r21matrix-m-malaria-vaccine-receives-who-recommendation-use-paving-way-global](https://www.ox.ac.uk/news/2023-10-02-oxford-r21matrix-m-malaria-vaccine-receives-who-recommendation-use-paving-way-global) (accessed
776 February 9 2024).
 - 777 16. Gardner MJ, Hall N, Fung E, et al. Genome sequence of the human malaria parasite
778 Plasmodium falciparum. *Nature* 2002; **419**(6906): 498-511.
 - 779 17. Cockburn IA, Seder RA. Malaria prevention: from immunological concepts to effective
780 vaccines and protective antibodies. *Nature Immunology* 2018; **19**(11): 1199-211.
 - 781 18. Kirchner S, Power BJ, Waters AP. Recent advances in malaria genomics and
782 epigenomics. *Genome Medicine* 2016; **8**(1): 92.

- 783 19. Bonam SR, Rénia L, Tadepalli G, Bayry J, Kumar HMS. Plasmodium falciparum
784 Malaria Vaccines and Vaccine Adjuvants. *Vaccines* 2021; **9**(10): 1072.
- 785 20. Coppel RL. Vaccinating with the genome: a Sisyphean task? *Trends in Parasitology*
786 2009; **25**(5): 205-12.
- 787 21. Pandey I, Quadiri A, Wadi I, Pillai CR, Singh AP, Das A. Conserved Plasmodium
788 Protein (PF3D7_0406000) of Unknown Function: In-silico Analysis and Cellular Localization.
789 *Infection, Genetics and Evolution* 2021; **92**: 104848.
- 790 22. Mu J, Awadalla P, Duan J, et al. Genome-wide variation and identification of vaccine
791 targets in the Plasmodium falciparum genome. *Nature Genetics* 2007; **39**(1): 126-30.
- 792 23. Goodswen SJ, Kennedy PJ, Ellis JT. A guide to current methodology and usage of
793 reverse vaccinology towards in silico vaccine discovery. *FEMS Microbiology Reviews* 2023;
794 **47**(2).
- 795 24. Beeson JG, Kurtovic L, Dobaño C, et al. Challenges and strategies for developing
796 efficacious and long-lasting malaria vaccines. *Science Translational Medicine* 2019; **11**(474):
797 eaau1458.
- 798 25. Naung MT, Martin E, Munro J, et al. Global diversity and balancing selection of 23
799 leading Plasmodium falciparum candidate vaccine antigens. *PLOS Computational Biology* 2022;
800 **18**(2): e1009801.
- 801 26. Olotu A, Fegan G, Wambua J, et al. Seven-Year Efficacy of RTS,S/AS01 Malaria
802 Vaccine among Young African Children. *New England Journal of Medicine* 2016; **374**(26):
803 2519-29.
- 804 27. CTP. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose
805 in infants and children in Africa: final results of a phase 3, individually randomised, controlled
806 trial. *The Lancet* 2015; **386**(9988): 31-45.
- 807 28. de Vrieze J. First malaria vaccine rolled out in Africa—despite limited efficacy and
808 nagging safety concerns. 2019. [https://www.science.org/content/article/first-malaria-vaccine-
809 rolled-out-africa-despite-limited-efficacy-and-nagging-safety](https://www.science.org/content/article/first-malaria-vaccine-rolled-out-africa-despite-limited-efficacy-and-nagging-safety).
- 810 29. Pringle JC, Carpi G, Almagro-Garcia J, et al. RTS,S/AS01 malaria vaccine mismatch
811 observed among Plasmodium falciparum isolates from southern and central Africa and globally.
812 *Scientific Reports* 2018; **8**(1): 6622.
- 813 30. Bell GJ, Agnandji ST, Asante KP, et al. Impacts of Ecology, Parasite Antigenic
814 Variation, and Human Genetics on RTS,S/AS01e Malaria Vaccine Efficacy. *Current*
815 *Epidemiology Reports* 2021; **8**(3): 79-88.
- 816 31. Preston MD, Campino S, Assefa SA, et al. A barcode of organellar genome
817 polymorphisms identifies the geographic origin of Plasmodium falciparum strains. *Nature*
818 *Communications* 2014; **5**(1): 4052.
- 819 32. Bailey JA, Mvalo T, Aragam N, et al. Use of Massively Parallel Pyrosequencing to
820 Evaluate the Diversity of and Selection on Plasmodium falciparum csp T-Cell Epitopes in
821 Lilongwe, Malawi. *The Journal of Infectious Diseases* 2012; **206**(4): 580-7.
- 822 33. Neafsey DE, Juraska M, Bedford T, et al. Genetic Diversity and Protective Efficacy of
823 the RTS,S/AS01 Malaria Vaccine. *New England Journal of Medicine* 2015; **373**(21): 2025-37.
- 824 34. Mangou K, Moore AJ, Thiam LG, et al. Structure-guided insights into potential function
825 of novel genetic variants in the malaria vaccine candidate PfRh5. *Scientific Reports* 2022; **12**(1):
826 19403.
- 827 35. Zhang H, Wang L, Compans RW, Wang B-Z. Universal Influenza Vaccines, a Dream to
828 Be Realized Soon. *Viruses* 2014; **6**(5): 1974-91.

- 829 36. Bullard BL, Weaver EA. Strategies Targeting Hemagglutinin as a Universal Influenza
830 Vaccine. *Vaccines* 2021; **9**(3): 257.
- 831 37. Giuliani MM, Adu-Bobie J, Comanducci M, et al. A universal vaccine for serogroup B
832 meningococcus. *Proceedings of the National Academy of Sciences* 2006; **103**(29): 10834-9.
- 833 38. Somé AF, Bazié T, Zongo I, et al. Plasmodium falciparum msp1 and msp2 genetic
834 diversity and allele frequencies in parasites isolated from symptomatic malaria patients in Bobo-
835 Dioulasso, Burkina Faso. *Parasites & Vectors* 2018; **11**(1): 323.
- 836 39. Nirmolia T, Ahmed MA, Sathishkumar V, et al. Genetic diversity of Plasmodium
837 falciparum AMA-1 antigen from the Northeast Indian state of Tripura and comparison with
838 global sequences: implications for vaccine development. *Malaria Journal* 2022; **21**(1): 62.
- 839 40. Sookpongthai P, Utayopas K, Sitthiyotha T, et al. Global diversity of the gene encoding
840 the Pfs25 protein—a Plasmodium falciparum transmission-blocking vaccine candidate. *Parasites
841 & Vectors* 2021; **14**(1): 571.
- 842 41. Ouattara A, Dwivedi A, Adams M, et al. An In Silico Analysis of Malaria Pre-
843 Erythrocytic-Stage Antigens Interpreting Worldwide Genetic Data to Suggest Vaccine Candidate
844 Variants and Epitopes. *Microorganisms* 2022; **10**(6): 1090.
- 845 42. WHO. World malaria report 2023. 2023. [https://www.who.int/teams/global-malaria-
846 programme/reports/world-malaria-report-2023](https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2023) (accessed February 3 2024).
- 847 43. Fola AA, He Q, Xie S, et al. Genomics reveals heterogeneous Plasmodium falciparum
848 transmission and selection signals in Zambia. *Communications Medicine* 2024; **4**(1): 67.
- 849 44. Ministry of Health Zambia M. Zambia National Malaria Indicator Survey Report. 2015
850 2019. <https://www.path.org/resources/zambia-natl-malaria-indicator-survey-mis-2018/> (accessed
851 November 25 2020).
- 852 45. Ippolito MM, Gebhardt ME, Ferriss E, et al. Scientific Findings of the Southern and
853 Central Africa International Center of Excellence for Malaria Research: Ten Years of Malaria
854 Control Impact Assessments in Hypo-, Meso-, and Holoendemic Transmission Zones in Zambia
855 and Zimbabwe. *The American Journal of Tropical Medicine and Hygiene* 2022; **107**(4_Suppl):
856 55-67.
- 857 46. Fola AA, Dorman J, Levy M, Ciubotariu I, Carpi G. Optimized HT gDNA extraction
858 from Dried Blood Spot using QIAcube HT for Malaria Genomic Epidemiology Studies. 2020.
859 [https://www.protocols.io/view/optimized-ht-gdna-extraction-from-dried-blood-spot-
860 j8nlkej3115r/v1](https://www.protocols.io/view/optimized-ht-gdna-extraction-from-dried-blood-spot-j8nlkej3115r/v1).
- 861 47. Choudhary S. pysradb: A Python package to query next-generation sequencing metadata
862 and data from NCBI Sequence Read Archive [version 1; peer review: 2 approved].
863 *F1000Research* 2019; **8**(532).
- 864 48. Carpi G, Gorenstein L, Harkins TT, Samadi M, Vats P. A GPU-accelerated compute
865 framework for pathogen genomic variant identification to aid genomic epidemiology of
866 infectious disease: a malaria case study. *Briefings in Bioinformatics* 2022; **23**(5).
- 867 49. Li H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM.
868 *arXiv: Genomics* 2013.
- 869 50. McKenna A, Hanna M, Banks E, et al. The Genome Analysis Toolkit: a MapReduce
870 framework for analyzing next-generation DNA sequencing data. *Genome Res* 2010; **20**(9): 1297-
871 303.
- 872 51. DePristo MA, Banks E, Poplin R, et al. A framework for variation discovery and
873 genotyping using next-generation DNA sequencing data. *Nat Genet* 2011; **43**(5): 491-8.

- 874 52. Miles A, Iqbal Z, Vauterin P, et al. Indels, structural variation, and recombination drive
875 genomic diversity in *Plasmodium falciparum*. *Genome Res* 2016; **26**(9): 1288-99.
- 876 53. Cingolani P, Platts A, Wang LL, et al. A program for annotating and predicting the
877 effects of single nucleotide polymorphisms, SnpEff. *Fly* 2012; **6**(2): 80-92.
- 878 54. Manske M, Miotto O, Campino S, et al. Analysis of *Plasmodium falciparum* diversity in
879 natural infections by deep sequencing. *Nature* 2012; **487**(7407): 375-9.
- 880 55. Rausch KM, Barnafo EK, Lambert LE, et al. Preclinical evaluations of Pfs25-EPA and
881 Pfs230D1-EPA in AS01 for a vaccine to reduce malaria transmission. *iScience* 2023; **26**(7).
- 882 56. Duffy PE. The Virtues and Vices of Pfs230: From Vaccine Concept to Vaccine
883 Candidate. *The American Journal of Tropical Medicine and Hygiene* 2022; **107**(3_Suppl): 17-21.
- 884 57. Silk SE, Kalinga WF, Mtaka IM, et al. Superior antibody immunogenicity of a viral-
885 vectored RH5 blood-stage malaria vaccine in Tanzanian infants as compared to adults. *Med*
886 *2023*.
- 887 58. Schwartz L, Brown GV, Genton B, Moorthy VS. A review of malaria vaccine clinical
888 projects based on the WHO rainbow table. *Malaria Journal* 2012; **11**(1): 11.
- 889 59. Molina-Cruz A, Barillas-Mury C. Pfs47 as a Malaria Transmission-Blocking Vaccine
890 Target. *The American Journal of Tropical Medicine and Hygiene* 2022; **107**(3_Suppl): 27-31.
- 891 60. Rozas J, Ferrer-Mata A, Sánchez-DelBarrio JC, et al. DnaSP 6: DNA Sequence
892 Polymorphism Analysis of Large Data Sets. *Molecular Biology and Evolution* 2017; **34**(12):
893 3299-302.
- 894 61. Nei M, Li WH. Mathematical model for studying genetic variation in terms of restriction
895 endonucleases. *Proceedings of the National Academy of Sciences* 1979; **76**(10): 5269-73.
- 896 62. Tajima F. Statistical method for testing the neutral mutation hypothesis by DNA
897 polymorphism. *Genetics* 1989; **123**(3): 585-95.
- 898 63. Nei M, Tajima F. DNA polymorphism detectable by restriction endonucleases. *Genetics*
899 *1981*; **97**(1): 145-63.
- 900 64. Leigh JW, Bryant D. popart: full-feature software for haplotype network construction.
901 *Methods in Ecology and Evolution* 2015; **6**(9): 1110-6.
- 902 65. Clement M, Snell Q, Walke P, Posada D, Crandall K. TCS: estimating gene genealogies.
903 Proceedings 16th International Parallel and Distributed Processing Symposium; 2002 15-19
904 April 2002; 2002. p. 7 pp.
- 905 66. Jumper J, Evans R, Pritzel A, et al. Highly accurate protein structure prediction with
906 AlphaFold. *Nature* 2021; **596**(7873): 583-9.
- 907 67. Reva BA, Finkelstein AV, Skolnick J. What is the probability of a chance prediction of a
908 protein structure with an rmsd of 6 Å? *Folding and Design* 1998; **3**(2): 141-7.
- 909 68. Chothia C, Lesk AM. The relation between the divergence of sequence and structure in
910 proteins. *The EMBO Journal* 1986; **5**(4): 823-6.
- 911 69. Mirdita M, Schütze K, Moriwaki Y, Heo L, Ovchinnikov S, Steinegger M. ColabFold:
912 making protein folding accessible to all. *Nature Methods* 2022; **19**(6): 679-82.
- 913 70. Guy AJ, Irani V, Richards JS, Ramsland PA. BioStructMap: a Python tool for integration
914 of protein structure and sequence-based features. *Bioinformatics* 2018; **34**(22): 3942-4.
- 915 71. Guy AJ, Irani V, Beeson JG, et al. Proteome-wide mapping of immune features onto
916 *Plasmodium* protein three-dimensional structures. *Scientific Reports* 2018; **8**(1): 4355.
- 917 72. Ramaraj T, Angel T, Dratz EA, Jesaitis AJ, Mumei B. Antigen-antibody interface
918 properties: Composition, residue interactions, and features of 53 non-redundant structures.
919 *Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics* 2012; **1824**(3): 520-32.

- 920 73. MalariaGEN. Genomic epidemiology of artemisinin resistant malaria. *eLife* 2016; **5**:
921 e08714.
- 922 74. Beutler N, Pholcharee T, Oyen D, et al. A novel CSP C-terminal epitope targeted by an
923 antibody with protective activity against *Plasmodium falciparum*. *PLOS Pathogens* 2022; **18**(3):
924 e1010409.
- 925 75. Coley AM, Gupta A, Murphy VJ, et al. Structure of the Malaria Antigen AMA1 in
926 Complex with a Growth-Inhibitory Antibody. *PLOS Pathogens* 2007; **3**(9): e138.
- 927 76. Bai T, Becker M, Gupta A, et al. Structure of AMA1 from *Plasmodium falciparum*
928 reveals a clustering of polymorphisms that surround a conserved hydrophobic pocket. *Proc Natl*
929 *Acad Sci U S A* 2005; **102**(36): 12736-41.
- 930 77. Dutta S, Lee SY, Batchelor AH, Lanar DE. Structural basis of antigenic escape of a
931 malaria vaccine candidate. *Proceedings of the National Academy of Sciences of the United States*
932 *of America* 2007; **104**(30): 12488-93.
- 933 78. Jimah JR, Salinas ND, Sala-Rabanal M, et al. Malaria parasite CelTOS targets the inner
934 leaflet of cell membranes for pore-dependent disruption. *Elife* 2016; **5**.
- 935 79. Patel PN, Dickey TH, Hopp CS, et al. Neutralizing and interfering human antibodies
936 define the structural and mechanistic basis for antigenic diversion. *Nature Communications*
937 2022; **13**(1): 5888.
- 938 80. Wright KE, Hjerrild KA, Bartlett J, et al. Structure of malaria invasion protein RH5 with
939 erythrocyte basigin and blocking antibodies. *Nature* 2014; **515**(7527): 427-30.
- 940 81. Alanine DGW, Quinkert D, Kumarasingha R, et al. Human Antibodies that Slow
941 Erythrocyte Invasion Potentiate Malaria-Neutralizing Antibodies. *Cell* 2019; **178**(1): 216-28.e21.
- 942 82. Ragotte RJ, Pulido D, Lias AM, et al. Heterotypic interactions drive antibody synergy
943 against a malaria vaccine candidate. *Nature Communications* 2022; **13**(1): 933.
- 944 83. Lennartz F, Brod F, Dabbs R, et al. Structural basis for recognition of the malaria vaccine
945 candidate Pfs48/45 by a transmission blocking antibody. *Nature Communications* 2018; **9**(1):
946 3822.
- 947 84. Ochwedo KO, Onyango SA, Omondi CJ, et al. Signatures of selection and drivers for
948 novel mutation on transmission-blocking vaccine candidate Pfs25 gene in western Kenya. *PLOS*
949 *ONE* 2022; **17**(4): e0266394.
- 950 85. Kaslow DC, Quakyi IA, Keister DB. Minimal variation in a vaccine candidate from the
951 sexual stage of *Plasmodium falciparum*. *Molecular and Biochemical Parasitology* 1989; **32**(1):
952 101-3.
- 953 86. Duffy PE, Kaslow DC. A novel malaria protein, Pfs28, and Pfs25 are genetically linked
954 and synergistic as *falciparum* malaria transmission-blocking vaccines. *Infection and Immunity*
955 1997; **65**(3): 1109-13.
- 956 87. Singh K, Burkhardt M, Nakuchima S, et al. Structure and function of a malaria
957 transmission blocking vaccine targeting Pfs230 and Pfs230-Pfs48/45 proteins. *Communications*
958 *Biology* 2020; **3**(1): 395.
- 959 88. Weiss GE, Crabb BS, Gilson PR. Overlaying Molecular and Temporal Aspects of
960 Malaria Parasite Invasion. *Trends in Parasitology* 2016; **32**(4): 284-95.
- 961 89. Scally SW, Murugan R, Bosch A, et al. Rare PfCSP C-terminal antibodies induced by
962 live sporozoite vaccination are ineffective against malaria infection. *Journal of Experimental*
963 *Medicine* 2017; **215**(1): 63-75.

- 964 90. Pholcharee T, Oyen D, Flores-Garcia Y, et al. Structural and biophysical correlation of
965 anti-NANP antibodies with in vivo protection against *P. falciparum*. *Nature Communications*
966 2021; **12**(1): 1063.
- 967 91. Basu M, Maji AK, Mitra M, Sengupta S. Natural selection and population genetic
968 structure of domain-I of Plasmodium falciparum apical membrane antigen-1 in India. *Infection,*
969 *Genetics and Evolution* 2013; **18**: 247-56.
- 970 92. Collins CR, Withers-Martinez C, Hackett F, Blackman MJ. An Inhibitory Antibody
971 Blocks Interactions between Components of the Malarial Invasion Machinery. *PLOS Pathogens*
972 2009; **5**(1): e1000273.
- 973 93. Ghoshal S, Chowdhury P, Ray S, et al. Population genetic and biophysical evidences
974 reveal that purifying selection shapes the genetic landscape of Plasmodium falciparum RH
975 ligands in Chhattisgarh and West Bengal, India. *Malaria Journal* 2020; **19**(1): 367.
- 976 94. van Schaijk BCL, van Dijk MR, van de Vegte-Bolmer M, et al. Pfs47, paralog of the
977 male fertility factor Pfs48/45, is a female specific surface protein in Plasmodium falciparum.
978 *Molecular and Biochemical Parasitology* 2006; **149**(2): 216-22.
- 979 95. van Dijk MR, Janse CJ, Thompson J, et al. A Central Role for P48/45 in Malaria Parasite
980 Male Gamete Fertility. *Cell* 2001; **104**(1): 153-64.
- 981 96. Eksi S, Czesny B, Van Gemert G-J, Sauerwein RW, Eling W, Williamson KC. Malaria
982 transmission-blocking antigen, Pfs230, mediates human red blood cell binding to exflagellating
983 male parasites and oocyst production. *Molecular Microbiology* 2006; **61**(4): 991-8.
- 984 97. Fabra-García A, Hailemariam S, de Jong RM, et al. Highly potent, naturally acquired
985 human monoclonal antibodies against Pfs48/45 block Plasmodium falciparum transmission to
986 mosquitoes. *Immunity* 2023; **56**(2): 406-19.e7.
- 987 98. Ko K-T, Lennartz F, Mekhaieel D, et al. Structure of the malaria vaccine candidate
988 Pfs48/45 and its recognition by transmission blocking antibodies. *Nature Communications* 2022;
989 **13**(1): 5603.
- 990 99. Coelho CH, Tang WK, Burkhardt M, et al. A human monoclonal antibody blocks malaria
991 transmission and defines a highly conserved neutralizing epitope on gametes. *Nature*
992 *Communications* 2021; **12**(1): 1750.
- 993 100. Ivanochko D, Fabra-García A, Teelen K, et al. Potent transmission-blocking monoclonal
994 antibodies from naturally exposed individuals target a conserved epitope on Plasmodium
995 falciparum Pfs230. *Immunity* 2023; **56**(2): 420-32.e7.
- 996 101. Tang WK, Coelho CH, Miura K, et al. A human antibody epitope map of Pfs230D1
997 derived from analysis of individuals vaccinated with a malaria transmission-blocking vaccine.
998 *Immunity* 2023; **56**(2): 433-43.e5.
- 999 102. Canepa GE, Molina-Cruz A, Yenkoidiok-Douti L, et al. Antibody targeting of a specific
1000 region of Pfs47 blocks Plasmodium falciparum malaria transmission. *npj Vaccines* 2018; **3**(1):
1001 26.
- 1002 103. Stowers AW, Keister DB, Muratova O, Kaslow DC. A Region of *Plasmodium*
1003 *falciparum* Antigen Pfs25 That Is the Target of Highly Potent Transmission-Blocking
1004 Antibodies. *Infection and Immunity* 2000; **68**(10): 5530-8.
- 1005 104. Kaslow DC. Immunogenicity of Plasmodium falciparum sexual stage antigens:
1006 Implications for the design of a transmission blocking vaccine. *Immunology Letters* 1990; **25**(1):
1007 83-6.

- 1008 105. Barr PJ, Green KM, Gibson HL, Bathurst IC, Quakyi IA, Kaslow DC. Recombinant
1009 Pfs25 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in
1010 experimental animals. *Journal of Experimental Medicine* 1991; **174**(5): 1203-8.
- 1011 106. Miura K, Keister DB, Muratova OV, Sattabongkot J, Long CA, Saul A. Transmission-
1012 blocking activity induced by malaria vaccine candidates Pfs25/Pvs25 is a direct and predictable
1013 function of antibody titer. *Malaria Journal* 2007; **6**(1): 107.
- 1014 107. Scally SW, McLeod B, Bosch A, et al. Molecular definition of multiple sites of antibody
1015 inhibition of malaria transmission-blocking vaccine antigen Pfs25. *Nature Communications*
1016 2017; **8**(1): 1568.
- 1017 108. McLeod B, Miura K, Scally SW, et al. Potent antibody lineage against malaria
1018 transmission elicited by human vaccination with Pfs25. *Nature Communications* 2019; **10**(1):
1019 4328.
- 1020 109. Gozar MMG, Price VL, Kaslow DC. Saccharomyces cerevisiae-Secreted Fusion Proteins
1021 Pfs25 and Pfs28 Elicit Potent Plasmodium falciparum Transmission-Blocking Antibodies in
1022 Mice. *Infection and Immunity* 1998; **66**(1): 59-64.
- 1023 110. Qian F, Aebig JA, Reiter K, et al. Enhanced antibody responses to Plasmodium
1024 falciparum Pfs28 induced in mice by conjugation to ExoProtein A of Pseudomonas aeruginosa
1025 with an improved procedure. *Microbes and Infection* 2009; **11**(3): 408-12.
- 1026 111. Menon V, Kapulu MC, Taylor I, et al. Assessment of Antibodies Induced by Multivalent
1027 Transmission-Blocking Malaria Vaccines. *Frontiers in Immunology* 2018; **8**.
- 1028 112. Gregory JA, Li F, Tomosada LM, et al. Algae-Produced Pfs25 Elicits Antibodies That
1029 Inhibit Malaria Transmission. *PLOS ONE* 2012; **7**(5): e37179.
- 1030 113. Pirahmadi S, Zakeri S, A. Mehrizi A, et al. Cell-traversal protein for ookinetes and
1031 sporozoites (CelTOS) formulated with potent TLR adjuvants induces high-affinity antibodies
1032 that inhibit Plasmodium falciparum infection in Anopheles stephensi. *Malaria Journal* 2019;
1033 **18**(1): 146.
- 1034 114. Chen L, Xu Y, Healer J, et al. Crystal structure of PfRh5, an essential P. falciparum
1035 ligand for invasion of human erythrocytes. *eLife* 2014; **3**: e04187.
- 1036 115. Campeotto I, Goldenzweig A, Davey J, et al. One-step design of a stable variant of the
1037 malaria invasion protein RH5 for use as a vaccine immunogen. *Proceedings of the National
1038 Academy of Sciences* 2017; **114**(5): 998-1002.
- 1039 116. Pizarro JC, Chitarra V, Verger D, et al. Crystal Structure of a Fab Complex Formed with
1040 PfMSP1-19, the C-terminal Fragment of Merozoite Surface Protein 1 from Plasmodium
1041 falciparum: A Malaria Vaccine Candidate. *Journal of Molecular Biology* 2003; **328**(5): 1091-
1042 103.
- 1043 117. Thouvenel CD, Fontana MF, Netland J, et al. Multimeric antibodies from antigen-
1044 specific human IgM+ memory B cells restrict Plasmodium parasites. *Journal of Experimental
1045 Medicine* 2021; **218**(4).
- 1046 118. MacDonald NJ, Singh K, Reiter K, et al. Structural and immunological differences in
1047 Plasmodium falciparum sexual stage transmission-blocking vaccines comprised of Pfs25-EPA
1048 nanoparticles. *npj Vaccines* 2023; **8**(1): 56.
- 1049 119. McLeod B, Mabrouk MT, Miura K, et al. Vaccination with a structure-based stabilized
1050 version of malarial antigen Pfs48/45 elicits ultra-potent transmission-blocking antibody
1051 responses. *Immunity* 2022; **55**(9): 1680-92.e8.
- 1052 120. Kundu P, Semesi A, Jore MM, et al. Structural delineation of potent transmission-
1053 blocking epitope I on malaria antigen Pfs48/45. *Nature Communications* 2018; **9**(1): 4458.

1054 121. Shukla N, Tang WK, Tolia NH. Structural analysis of Plasmodium falciparum ookinete
1055 surface antigen Pfs28 relevant for malaria vaccine design. *Scientific Reports* 2022; **12**(1): 19556.
1056